RxDoctor Payments Data

John Kelly, MD

Neurology · Wasilla, AKNPI 1407855315

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,588 of the $12,929 with a category attached, or 66.4%. TG Therapeutics, Inc. accounts for 72.9% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $9,946, more than ten times the $138 reported in 2019.

$12,929in general payments, 2019–2025

Across 175 payments — averaging $73.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$9K
  • AbbVie$477
  • AstraZeneca$271
  • UCB, Inc.$205
  • EMD Serono, Inc.$203
  • Sanofi$196
  • plus $2K from 31 others

What the payments were for

  • Speaking & faculty fees$8,58866%
  • Food & beverage$4,22533%
  • Education$1161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,929 in reported general payments places this provider in the 85th percentile of 21 neurology providers in Alaska.

See all neurology providers in Alaska

Medicare billing

Part B allowed, 2024
$530,832
Medicare patients
294
Services billed
23,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lamotrigine ErLamotrigine16$1,881
Memantine Hcl30$1,336
Entacapone11$848
Carbidopa-LevodopaCarbidopa/Levodopa24$772
Levetiracetam22$691
Primidone42$649
Donepezil Hcl53$643
Lamotrigine25$320
Baclofen13$239
ClopidogrelClopidogrel Bisulfate14$190
Gabapentin14$138
Topiramate11$93

Paid to pharmacies, not to this prescriber.

Other neurology in Wasilla

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →